Navigation Links
Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors
Date:7/27/2009

SOUTH SAN FRANCISCO, Calif., July 27 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Helen S. Kim has been appointed to the company's Board of Directors, effective immediately. Ms. Kim is a designee of New Enterprise Associates, which purchased approximately $2.3 million of the company's securities in the initial closing of the company's recent private placement.

"We are pleased to have Helen join the Sunesis Board of Directors," said Daniel Swisher, Sunesis' Chief Executive Officer. "Helen brings a wealth of experience in corporate development as well as strategic marketing. We believe Helen's proven leadership, successful business development track record and commercial insights will benefit Sunesis significantly."

Ms. Kim is currently a Director and Chief Executive Officer of privately held TRF Pharma, Inc. Previously, she was the Chief Executive Officer and President of Kosan Biosciences Incorporated where she restructured and repositioned the company prior to successfully selling the company to Bristol-Myers Squibb in 2008. Ms. Kim's additional industry experience includes senior positions at Affymax, Onyx Pharmaceuticals, Protein Design Labs and Chiron Corporation. In addition to her industry experience, Ms. Kim also recently served as Chief Program Officer for the Gordon and Betty Moore Foundation from 2003 to 2008. Ms. Kim received a B.S. in Chemical Engineering from Northwestern University and a M.B.A. from the University of Chicago.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of hematologic and solid cancers. Sunesis has built a highly experienced cancer drug development organiza
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
5. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
8. Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
9. Sunesis Reports Financial Results for the First Quarter 2009
10. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO
11. Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... discovered a group of new materials capable of ... award worth a combined 2m to find out ... lead to a significant reduction in hospital infections ... health care of hospital patients across the globe. ... the School of Pharmacy and Paul Williams, Professor ...
(Date:7/29/2014)... 2014 CHI-California Healthcare Institute today unveiled ... hepatitis C (hep C) epidemic in the U.S., the ... to reduce human suffering. The report examines key data ... hep C, while highlighting the significance of breakthroughs that ... CHI is a nonprofit, public policy research organization, representing ...
(Date:7/29/2014)... Salt Lake City, UT (PRWEB) July 29, 2014 ... about how Activz produce powders can help parents add ... Magazine article “Little Bites – Key market drivers ... Activz Whole-Food Nutrition, is pleased to announce the ... nutritional benefits of adding the Activz organic vegetable and ...
(Date:7/29/2014)... Researchers at Cold Spring Harbor Laboratory (CSHL) have discovered a ... p53, this protein has been called "the guardian of the ... sense damage to their DNA caused by stress, such as ... UV rays. If the damage is severe, p53 can ... Mutant versions of p53 that no longer perform this vital ...
(Date:7/29/2014)... July 29, 2014 – Silverado, a provider of memory care, ... it is a Bronze winner in the 35th Annual Telly ... a Child's Eye and Silverado Resident Visits Space ... Child's Eye , seven-year-old Mia Sandoval shares her experience coming ... memory care community in Los Angeles. The feel-good video highlights ...
Breaking Medicine News(10 mins):Health News:Bacteria resistant materials -- £2m to get the 'inside' story 2Health News:Bacteria resistant materials -- £2m to get the 'inside' story 3Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 2Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 3Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 4Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 2Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 3Health News:Research may explain how foremost anticancer 'guardian' protein learned to switch sides 2Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2
... people suffering from diabetes is already over 194 million ... 333 million by 2025. Type II diabetes is also ... by a relative disparity between endogenous insulin production and ... to Type I diabetes, there is always some endogenous ...
... cases has reached about 1.2 million worldwide and Statistics show ... urban India and has overtaken cancer of the cervix as ... according to a study conducted on women and cancer in ... motherhood are some factors that can lead to a high ...
... antibiotics may be used to treat childhood cholera. ... children can be treated effectively with a single dose ... study published online by The Lancet., ,Cholera is ... areas in less-developed countries. In the resource-limited countries where ...
... Professor Alice Sigurdson and Colleagues has reported the dosage ... which increases the risk of thyroid cancer. ... were treated for thyroid cancer during their childhood. The ... risk of developing thyroid cancer and there seems to ...
... less at risk from developing the dreaded disease of ... recent issue of Archives of Neurology. ,In previous ... course of a MS-like disease in animals, suggesting that ... postpartum period afterward, both states associated with profound hormonal ...
... children who survive cancer have about twice the rate ... a history of cancer. The study finds children ... children treated with cranial radiation therapy (CRT) are at ... ,As therapies for childhood cancers have become more ...
Cached Medicine News:Health News:Sitagliptin, Under Investigation For Type 2 Diabetes 2Health News:Risk of Thyroid cancer is increased after Childhood Irradiation of Neck region 2Health News:Socialization A Serious Trouble For Childhood Cancer Survivors 2
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- MHG Medical ... has launched its Medical Equipment and X-ray ... services are tailored to the cruise industry,s unique ... industry operators to propose that they should develop ... new program is intended to create standardized processes ...
(Date:7/29/2014)... July 29, 2014  Instrumentation Laboratory (IL) today announced the ... corporate logo. This is part of a comprehensive rebranding effort ... in Boston, MA , in 1959, IL ... since 1992.  Other companies in the group include Inova Diagnostics ... ( Barcelona, Spain ).  Like IL, these three ...
(Date:7/29/2014)... Cynosure, Inc. (Nasdaq: ... aesthetic treatment systems for high-volume applications, today reported financial ... Second-quarter 2014 financial results incorporate the acquisition of Palomar ... Second-Quarter 2014 Financial Highlights ... million , Non-GAAP net income of $7.1 million, ...
Breaking Medicine Technology:MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12
... PHILADELPHIA, November 10 , ... of Excellence in Serving,Healthcare Needs of Patients in California, ... Elsevier ( http://www.elsevier.com ), a world leader ... that Trinity Health,( http://www.trinity-health.org ), the nation,s fourth largest ...
... SAN DIEGO, Nov. 9 Volcano Corporation (Nasdaq: ... sales of products for the diagnosis and treatment of ... will be participating in the Third Annual Canaccord Cardiovascular ... Scott Huennekens, president and chief executive officer, will begin ...
Cached Medicine Technology:Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States 2Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States 3Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States 4Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 2
Multi-constituent normal and abnormal plasma controls for routine and specialty assays performed on the STA© family of hemostasis analyzers....
PT, PTT, Fibrinogetn & TT Normal and Abnormal Controls...
Fructosamine Calibrator...
ApolipoproteinA-1 & B Calibrator...
Medicine Products: